1)Kumar S, Paiva B, Anderson KC, et al:International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328-e346,2016
2)Paiva B, Puig N, Cedena MT, et al:Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. J Clin Oncol 38:784-792,2020
3)高松博幸:多発性骨髄腫における微小残存病変検査とその臨床的意義.臨血 59:2153-2161,2018
4)丸岡隼人,白石祐美,吉岡聡,他:マルチパラメトリックフローサイトメトリーを用いた高感度測定可能残存病変解析.日検血会誌 21:422-429,2020
5)田邊正喜:多発性骨髄腫の検査.日検血会誌 21:365-371,2020
6)Nijhof IS, Casneuf T, van Velzen J, et al:CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128:959-970,2016
7)Krejcik J, Frerichs KA, Nijhof IS, et al:Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clin Cancer Res 23:7498-7511,2017
8)Soh KT, Tario JD Jr, Hahn T, et al:CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry B Clin Cytom 100:497-508,2021